PRRT was approved in USA on 26 Jan 2018. The approval is for the treatment of somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults. CLICK HERE.
The extended access program (trial) is no longer offered but these locations should be ahead of the game in terms of provision, notwithstanding insurance and provision of sufficient nuclear material.
Read more about PRRT by clicking here
Thanks for reading
I’m also active on Facebook. Like my page for even more news. I’m also building up this site here: Ronny Allan
My Diagnosis and Treatment History
Sign up for my twitter newsletter
Remember ….. in the war on Neuroendocrine Cancer, let’s not forget to win the battle for better quality of life!
Please Share this post
Please Share this post for Neuroendocrine Cancer awareness and to help another patient
Discover more from Ronny Allan - Living with Neuroendocrine Cancer
Subscribe to get the latest posts sent to your email.
[…] Ronny’s latest post – BREAKING NEWS – US FDA Approves Lutetium Lu 177 dotatate (Lutathera®) – PRRT? […]
Positive Reinforcement – Required Treatment
https://polldaddy.com/js/rating/rating.js
😊
Excellent research Ronny. Getting a global view of the current status will be very helpful to any folks unable to receive the PRRT in their homeland.
Big Thankyou for your continued efforts and sharing data as you receive it!!!
https://polldaddy.com/js/rating/rating.js